Citations

Clear

3942 citation(s) found for "To, Van".

Cardiovascular outcomes of pregnancy in Turner syndrome
Grewal, Jasmine , Valente, Anne Marie , Egbe, Alexander C. , Wu, Fred , Sybert, Virginia P., Hagen, Iris M. van , Beauchesne, Luc , Rodriguez, Fred H. , Broberg, Craig S. , John, Anitha S. , Bradley, Elisa A. , Roos‐Hesselink, Jolien W. , van Hagen, Iris M , John, Anitha , Roos-Hesselink, Jolien W , Bradley, Elisa A , Krieger, Eric V.

Mayo Clinic

Heart | July 15, 2020 | Volume: 107 | Issue: 1 | Pages: 61-66

10.1136/heartjnl-2020-316719 | PMID 32669396 Get It

Objectives Women with Turner syndrome (TS) are frequently counselled against pregnancy due to lack of data and unclear aortic dissection risk. However, with advances in fertility therapy, more women with TS are contemplating pregnancy. This study compared rates of adverse cardiovascular (CV) outcomes among: (1) pregnant and non-pregnant women with TS and (2) pregnant women with TS with/without structural heart disease. Methods Retrospective analysis of pregnant and age-matched non-pregnant controls with TS (2005–2017) across 10 CV centres was done. Data were collected at initial evaluation in pregnancy and outcomes were assessed to 6 months postpartum. Adverse CV events were defined as CV death, aortic dissection/rupture and/or aortic intervention. Non-pregnant age-matched controls were followed over the same time period. Results Sixty-eight pregnancies were included (60 women, mean age 33 years, 48% primigravid, 49% fertility therapy, 80% structurally normal heart, 25% XO karyotype). Based on American Society of Reproductive Medicine criteria, 10 pregnancies occurred in women stratified to high-risk category. There were no CV events in the pregnant women or in the non-pregnant women with TS. Obstetric events complicated 12 (18%) pregnancies with 9 (13%) attributed to hypertensive disorder of pregnancy. Fetal events included small for gestational age neonates (18%), preterm delivery (15%) and fetal death (3%). Conclusions This study helps to refine the approach to pregnancy in women with TS. Among women with TS without structural heart disease, pregnancy does not impose an increased risk of CV outcomes. Among women with TS with structural heart disease, the risk of pregnancy is not as prohibitive as previously described but does require ongoing evaluation.
Human Papillomavirus–Associated Anogenital Pathology in Females With HPV‐Positive Oropharyngeal Squamous Cell Carcinoma
Larish, Alyssa , Moore, Eric J. , Routman, David M. , Janus, Jeffrey R. , Price, Katharine A. , Neben-Wittich, M.A. , Foote, Robert L. , Abel, Kathryn M. Van , Yin, Linda, Glaser, Gretchen , Moore, Eric, Bakkum-Gamez, Jamie, Routman, David, Ma, Daniel, Price, Daniel, Janus, Jeffrey, Price, Katharine, Chintakuntlawar, Ashish, Neben-Wittich, Michelle, Foote, Robert, Van Abel, Kathryn, Van Abel, Kathryn M , Routman, David M , Yin, Linda X. , Bakkum‐Gamez, Jamie N. , Daniel, J. , Price, Daniel L. , Chintakuntlawar, Ashish V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 14, 2020 | Volume: 164 | Issue: 2 | Pages: 369-374

10.1177/0194599820941499 | PMID 32663054 Get It

We sought to determine the incidence and location of human papillomavirus (HPV)–associated anogenital disease in women with HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) via a retrospective cohort study with prospective contact to update history at Mayo Clinic in Rochester, Minnesota. Females undergoing treatment for nonmetastatic HPV‐positive OPSCC from 2011 to 2019 were identified. Clinical history and outcomes were abstracted from medical records. Patients without documented anogenital history were contacted, consented, and administered a survey, and external records were requested and reviewed. Seventeen of 46 patients (37.0%) had a history of anogenital HPV‐associated disease, and 16 of 17 (94.1%) required procedures to diagnose or treat HPV lesions. The cervix was the most common site (16/17, 94.1%). Procedures included colposcopy (n = 6), cervical excision (n = 3), cryotherapy (n = 4), and hysterectomy (n = 3). One case of fatal cervical carcinoma was noted, diagnosed 1 year following OPSCC. Three of 17 (17.6%) had HPV‐related vulvovaginal disease, and 1 of 17 had anal disease. Patients with a history of HPV‐positive OPSCC may be at elevated risk for HPV‐associated anogenital disease.
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas
Monga, Varun , Skubitz, Keith M. , Maliske, Seth , Mott, Sarah L. , Dietz, Hilary , Hirbe, Angela C. , Oppelt, Peter , Okuno, Scott H. , O’Connor, Madeline, Seetharam, ­Mahesh , Attia, Steven , Charlson, John A. , Agulnik, Mark , Milhem, Mohammed , Robinson, Steven, O'Connor, Madeline, Milhem, Mohammed M , Hirbe, Angela C , Skubitz, Keith , Monga, Varun , Tine, Brian A. Van , Oppelt, Peter, Robinson, Steven I.

Mayo Clinic

Cancers | July 14, 2020 | Volume: 12 | Issue: 7 | Pages: 1873

10.3390/cancers12071873 | PMID 32664595 Get It

Although checkpoint inhibitors have been approved in multiple cancers, they are still under investigation in soft tissue sarcoma (STS). We conducted a retrospective review to report the safety, efficacy, and prognostic factors related to checkpoint inhibitors in STS. A sequential cohort of metastatic STS patients from four institutions treated with checkpoint inhibitors was assembled. Logistic and Cox regression models were applied to determine the effect of patient characteristics, prior treatment, and baseline factors on achieving the best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by the treating physician. Eighty-eight patients with two median prior therapies received checkpoint inhibitors. Treatments included pembrolizumab in 47, nivolumab in 6, ipilimumab in 1, combination ipilimumab/nivolumab in 27, and other combination immunotherapies in 7 patients. Immunotherapy was discontinued in 54 patients—72.2% for progression, 16.7% for toxicity, and 11.1% for other reasons. Median progression-free survival (PFS) was 4.1 months and median overall survival was 19.1 months. One patient with undifferentiated pleomorphic sarcoma (UPS) achieved a CR, while 20 patients had a PR, including 7 UPS, 9 leiomyosarcoma (LMS), and 1 each with alveolar soft part sarcoma, fibroblastic sarcoma, sclerosing epithelioid fibrosarcoma, and myxofibrosarcoma. Forty-five percent (9 of 20) of LMS patients achieved a PR. Twenty-eight patients had SD. Our results confirm the activity and safety of anti-PD-1 therapy in metastatic STS. A notable response rate was observed in UPS and LMS subtypes. This study expands the knowledge base beyond what is currently available from clinical trials involving checkpoint inhibitors in metastatic STS.
A risk calculator predicting recurrence in lymph node metastatic penile cancer
Pederzoli, Filippo , Marandino, Laura , Brouwer, Oscar R. , Roussel, Eduard , Vries, Hielke M. de , Chipollini, Juan , Ye, Dingwei , Ornellas, Antônio Augusto , Heidenreich, Axel , Haidl, Friederike, Watkin, Nick , Ager, Michael , Karnes, Jeffrey , Briganti, Alberto , Montorsi, Francesco , Azizi, Mounsif , Larcher, Alessandro , Bandini, Marco , Pederzoli, Filippo , Marandino, Laura , Brouwer, Oscar R , Roussel, Eduard , Chipollini, Juan , Zhu, Yao , Ornellas, Antonio A , Heidenreich, Axel , Ager, Michael , Azizi, Mounsif , Necchi, Andrea , Spiess, Philippe E. , Albersen, Maarten , Catanzaro, Mario Achille , Hakenberg, Oliver Walter , Ahmed, Mohamed E. , Salvioni, Roberto , Necchi, Andrea

Mayo Clinic

BJU International | July 14, 2020 | Volume: 126 | Issue: 5 | Pages: 577-585

10.1111/bju.15177 | PMID 32662205 Get It

Objectives To develop and externally validate a risk calculator for prediction of any cancer recurrence in patients with penile squamous cell carcinoma (pSCC) and inguinal lymph node metastases (ILNM), as to date no validated prognostic tool is available for patients with pSCC and ILNM. Patients and Methods The development cohort included 234 patients from seven referral centres. The external validation cohort included 273 patients from two additional referral centres. Cox regression identified predictors of any recurrence, which were used to develop a risk calculator. The risk‐calculator grouped the development and the validation cohorts according to the individual risk of any recurrence at 24 months (24m‐R). Adjuvant treatment effects were tested on overall survival (OS) according to the derived tertiles, within the development and validation cohorts. Results Positive surgical margins, pN 3 , and ILNM ratio were associated with higher recurrence rate. The 2‐year OS rates were lower for patients with high (>37%) and intermediate (19–37%) compared to low (<19%) 24m‐R risk of recurrence, for both the development (43% and 58% vs 83%, P < 0.001) and validation cohort (44% and 50% vs 85%, P < 0.001). Results were confirmed in the subgroup of patients who did not receive adjuvant treatment ( P < 0.001), but not in patients who did receive adjuvant treatments in both the development and validation cohorts ( P > 0.1). Conclusion Adjuvant treatment planning is crucial in patients with pSCC with ILNM, where only weak evidence is available. The current tool proved to successfully stratify patients according to their individual risk, potentially allowing better tailoring of adjuvant treatments.
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design
Jaeckle, Kurt A. , Ballman, Karla V. , Bent, Martin J. van den , Giannini, Caterina , Galanis, Evanthia , Brown, Paul D. , Jenkins, Robert B. , Cairncross, J. Gregory , Wick, Wolfgang , Weller, Michael , Aldape, Kenneth , Anderson, S. Keith , Cerhan, Jane H. , Klein, Martin , Schiff, David , Raizer, Jeffrey J. , Dhermain, F., Nordstrom, Donald G., Flynn, Patrick J. , Vogelbaum, Michael A. , Dixon, Jesse G. , Weller, Michael , van den Bent, Martin J , Galanis, Evanthia , Giannini, Caterina , Wick, Wolfgang , Jaeckle, Kurt A , Ballman, Karla , Dixon, Jesse G , Dixon, Jesse G , Wefel, Jeffrey S. , Grossman, Stuart A.

Mayo Clinic

Neuro-Oncology | July 13, 2020 | Volume: 23 | Issue: 3 | Pages: 457-467

10.1093/neuonc/noaa168 | PMID 32678879 Get It

Abstract Background We report the analysis involving patients treated on the initial CODEL design. Methods Adults (&gt;18) with newly diagnosed 1p/19q World Health Organization (WHO) grade III oligodendroglioma were randomized to radiotherapy (RT; 5940 centigray ) alone (arm A); RT with concomitant and adjuvant temozolomide (TMZ) (arm B); or TMZ alone (arm C). Primary endpoint was overall survival (OS), arm A versus B. Secondary comparisons were performed for OS and progression-free survival (PFS), comparing pooled RT arms versus TMZ-alone arm. Results Thirty-six patients were randomized equally. At median follow-up of 7.5 years, 83.3% (10/12) TMZ-alone patients progressed, versus 37.5% (9/24) on the RT arms. PFS was significantly shorter in TMZ-alone patients compared with RT patients (hazard ratio [HR] = 3.12; 95% CI: 1.26, 7.69; P = 0.014). Death from disease progression occurred in 3/12 (25%) of TMZ-alone patients and 4/24 (16.7%) on the RT arms. OS did not statistically differ between arms (comparison underpowered). After adjustment for isocitrate dehydrogenase (IDH) status (mutated/wildtype) in a Cox regression model utilizing IDH and RT treatment status as covariables (arm C vs pooled arms A + B), PFS remained shorter for patients not receiving RT (HR = 3.33; 95% CI: 1.31, 8.45; P = 0.011), but not OS ((HR = 2.78; 95% CI: 0.58, 13.22, P = 0.20). Grade 3+ adverse events occurred in 25%, 42%, and 33% of patients (arms A, B, and C). There were no differences between arms in neurocognitive decline comparing baseline to 3 months. Conclusions TMZ-alone patients experienced significantly shorter PFS than patients treated on the RT arms. The ongoing CODEL trial has been redesigned to compare RT + PCV versus RT + TMZ.
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Annibali, Daniela , Ashton, Katie A. , Auer, Paul L. , Beckmann, Matthias W. , Black, Amanda , Brinton, Louise A. , Buchanan, Daniel D. , Chen, Chu , Chen, Maxine , Cheng, Timothy, Crous‐Bou, Marta , Vivo, Immaculata De , Dörk, Thilo , Dowdy, Sean C. , Easton, Douglas F. , Ekici, Arif B. , Fasching, Peter A. , García‐Closas, Montserrat , Gaudet, Mia M. , Goode, Ellen L. , Gorman, Maggie, Haiman, Christopher A. , Hankinson, Susan E. , Hein, Alexander , Hillemanns, Peter , Hodgson, Shirley, Høivik, Erling A. , Holliday, Elizabeth , Hunter, David J., Lambrechts, Diether , Liang, Xiaolin , Lindblom, Annika , Lissowska, Jolanta , Magliocco, Anthony M., Martin, Lynn , McEvoy, Mark , Mints, Miriam, Nassir, Rami , Otton, Geoffrey, Palles, Claire , Pooler, Loreall , Proietto, Tony, Rübner, Matthias, Runnebaum, Ingo B. , Sacerdote, Carlotta , Sarto, Gloria E., Scott, Rodney J. , Shah, Mitul , Sheng, Xin , Tomlinson, Ian , Trovik, Jone , Wang, Zhaoming , Wentzensen, Nicolas , Xia, Lucy , Webb, Penelope M. , Thompson, Deborah J. , Glubb, Dylan M., O’Mara, Tracy A. , Lambrechts, Diether , Buchanan, Daniel D , Chen, Chu , De Vivo, Immaculata , Dörk, Thilo , Fasching, Peter A , Friedenreich, Christine M , Gaudet, Mia M , Goode, Ellen L , Lu, Lingeng , Sacerdote, Carlotta , Shu, Xiao-Ou , Wang, Zhaoming , Wentzensen, Nicolas , Xiang, Yong‐Bing , Yu, Herbert , Spurdle, Amanda B , O'Mara, Tracy A , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Lissowska, Jolanta , Lambrechts, Diether , García-Closas, Montserrat , Ekici, Arif B , Nassir, Rami , Palles, Claire , Lindblom, Annika , Kho, Pik Fang , Amant, Frédéric , Attia, John , Chanock, Stephen Jacob , Cook, Linda S. , Czene, Kamila , Dennis, Joe , Dunning, Alison M. , Dürst, Matthias , Fridley, Brooke L. , Giles, Graham G. , Hall, Per N , Hankinson, Susan E. , Jones, Angela, Kraft, Peter , Krakstad, Camilla , Marchand, Loı̈c Le , Long, Jirong , Milne, Roger L. , Mints, Miriam , Rebbeck, Timothy R. , Renner, Stefan P. , Risch, Harvey A. , Schumacher, Fredrick R. , Setiawan, Veronica Wendy , Shu, Xiao‐Ou , Southey, Melissa C. , Tham, Emma , Turman, Constance , Tyrer, Jonathan P. , Berg, David Van Den , Yang, Hannah , Yu, Kai , Zheng, Wei , Spurdle, Amanda B.

Mayo Clinic

International Journal of Cancer | July 13, 2020 | Volume: 148 | Issue: 2 | Pages: 307-319

10.1002/ijc.33206 | PMID 32851660 Get It

Abstract Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ( P < 5 × 10 −8 ) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.
Arm Use In The Humeral Elevation Range Of Tendon Compression For Manual Wheelchair Users
Goodwin, Brianna M. , Straaten, Meegan G. Van , Jahanian, Omid , Cain, Stephen M. , Fortune, Emma , Morrow, Melissa M.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 293-293

10.1249/01.mss.0000676788.72545.ce Get It

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score
Kunchok, Amy , Lechner‐Scott, Jeannette , Granella, Franco, Alroughani, Raed , Sola, Patrizia , Lugaresi, Alessandra , Izquierdo, Guillermo , Grammond, Pierre , Sánchez-Menoyo, José Luis , Wijmeersch, Bart Van , Boz, Cavit , Grand’Maison, François , Spitaleri, Daniele , Hupperts, Raymond , Group, for the MSBase Study, Alroughani, Raed , Sormani, Maria P , Pittock, Sean J , Trojano, María , Ferraro, Diana , ONOFRJ, MARCO C. , Özakbaş, Serkan , Pucci, Eugenio , McCombe, Pamela , Vucic, Steve , Jokubaitis, Vilija , Sormani, Maria Pia , Butzkueven, Helmut , Kalinčík, Tomáš , Group, for the MSBase Study

Mayo Clinic

Multiple Sclerosis Journal | July 8, 2020 | Volume: 27 | Issue: 5 | Pages: 695-705

10.1177/1352458520936823 | PMID 32639855 Get It

Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing–remitting multiple sclerosis (RRMS) treated with interferon-β. Objective: To validate the MAGNIMS score and extend to other disease-modifying therapies (DMTs). To examine the prognostic value of gadolinium contrast-enhancing (Gd+) lesions. Methods: This RRMS MSBase cohort study ( n = 2293) used a Cox model to examine the prognostic value of relapses, MRI activity and the MAGNIMS score for disability worsening during treatment with interferon-β and three other DMTs. Results: Three new T2 lesions (hazard ratio (HR) = 1.60, p = 0.028) or two relapses (HR = 2.24, p = 0.002) on interferon-β (for 12 months) were predictive of disability worsening over 4 years. MAGNIMS score = 2 (1 relapse and ⩾3 T2 lesions or ⩾2 relapses) was associated with a greater risk of disability worsening on interferon-β (HR = 2.0, p = 0.001). In pooled cohort of four DMTs, similar associations were seen (MAGNIMS score = 2: HR = 1.72, p = 0.001). Secondary analyses demonstrated that the addition of Gd+ to the MAGNIMS did not materially improve its prediction of disability worsening. Conclusion: We have validated the MAGNIMS score in RRMS and extended its application to three other DMTs: 1 relapse and ⩾3 T2 lesions or ⩾2 relapses predicted worsening of disability. Contrast-enhancing lesions did not substantially improve the prognostic score.
Triage of patients with venous and lymphatic diseases during the COVID-19 pandemic – The Venous and Lymphatic Triage and Acuity Scale (VELTAS)
Parsi, Kurosh , Rij, André M. van , Meissner, Mark H. , Gloviczki, Péter , Benson, Stephen, Bottini, Oscar, Canata, Victor , Dinnen, Paul, Gasparis, Antonios, Gianesini, Sergio , Lal, Brajesh K. , Kabnick, Lowell S , Marston, William A. , Granados, Alberto Martinez, Morrison, Nick , Paraskevas, P, Patel, Malay , Roberts, Stefania , Komlos, Pedro, Varghese, Roy , Welch, Harold J. , Wittens, Cees H.A. , Parsi, Kurosh , Davies, Alun H. , Maeseneer, Marianne De , Huber, David, Jenkins, David, Lim, Adrian, Nicolaides, Andrew , Rogan, Christopher , Schul, Marlin W. , Stirling, Andy , Thibault, Simon , Gloviczki, Péter

Mayo Clinic

Phlebology: The Journal of Venous Disease | July 8, 2020 | Volume: 35 | Issue: 8 | Pages: 550-555

10.1177/0268355520930884 | PMID 32639862 Get It

The coronavirus disease 2019 (COVID-19) global pandemic has resulted in diversion of healthcare resources to the management of patients infected with SARS-CoV-2 virus. Elective interventions and surgical procedures in most countries have been postponed and operating room resources have been diverted to manage the pandemic. The Venous and Lymphatic Triage and Acuity Scale was developed to provide an international standard to rationalise and harmonise the management of patients with venous and lymphatic disorders or vascular anomalies. Triage urgency was determined based on clinical assessment of urgency with which a patient would require medical treatment or surgical intervention. Clinical conditions were classified into six categories of: (1) venous thromboembolism (VTE), (2) chronic venous disease, (3) vascular anomalies, (4) venous trauma, (5) venous compression and (6) lymphatic disease. Triage urgency was categorised into four groups and individual conditions were allocated to each class of triage. These included (1) medical emergencies (requiring immediate attendance), example massive pulmonary embolism; (2) urgent (to be seen as soon as possible), example deep vein thrombosis; (3) semi-urgent (to be attended to within 30–90 days), example highly symptomatic chronic venous disease, and (4) discretionary/non-urgent- (to be seen within 6–12 months), example chronic lymphoedema. Venous and Lymphatic Triage and Acuity Scale aims to standardise the triage of patients with venous and lymphatic disease or vascular anomalies by providing an international consensus-based classification of clinical categories and triage urgency. The scale may be used during pandemics such as the current COVID-19 crisis but may also be used as a general framework to classify urgency of the listed conditions.
Candida-Antigen Immune Reactivity in Subjects with Latent Tuberculosis Infection: A Shared Immunity?
Pennington, Kenneth R., Peikert, Tobias, Keulen, Virginia Van, Erskine, Courtney L. , Escalante, Patricio , Keulen, Virginia P. Van

Mayo Clinic

C106. BASIC AND TRANSLATIONAL DISCOVERIES IN TB AND MYCOBACTERIAL DISEASES | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6092-A6092

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6092 Get It